This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives (ceftaroline fosamil, cefiderocol, plazomicin, omadacycline, eravacycline, sarecycline, lefamulin, dalbavancin, oritavancin), and one natural product (fidaxomicin).
Keywords: Antibiotics; Antimicrobial resistance; Natural products; Semisynthesis; Tuberculosis.
Copyright 2023 Erik Jung, Karl Gademann. License: This work is licensed under a Creative Commons Attribution 4.0 International License.